These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Update on the systemic management of noninfectious uveitis in children and adolescents. Leal I; Steeples LR; Wong SW; Giuffrè C; Pockar S; Sharma V; Green EKY; Payne J; Jones NP; Chieng ASE; Ashworth J Surv Ophthalmol; 2024; 69(1):103-121. PubMed ID: 36682467 [TBL] [Abstract][Full Text] [Related]
4. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis. Thng ZX; Regenold J; Bromeo AJ; Akhavanrezayat A; Than NTT; Khatri A; Mohammadi SS; Tran ANT; Shin YU; Karaca I; Ghoraba HH; Or CCM; Nguyen QD Expert Opin Investig Drugs; 2024 Feb; 33(2):95-104. PubMed ID: 38299551 [TBL] [Abstract][Full Text] [Related]
5. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I. Lee K; Bajwa A; Freitas-Neto CA; Metzinger JL; Wentworth BA; Foster CS Expert Opin Pharmacother; 2014 Oct; 15(15):2141-54. PubMed ID: 25226529 [TBL] [Abstract][Full Text] [Related]
6. New therapies in development for the management of non-infectious uveitis: A review. Hassan M; Karkhur S; Bae JH; Halim MS; Ormaechea MS; Onghanseng N; Nguyen NV; Afridi R; Sepah YJ; Do DV; Nguyen QD Clin Exp Ophthalmol; 2019 Apr; 47(3):396-417. PubMed ID: 30938012 [TBL] [Abstract][Full Text] [Related]
7. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Rosenbaum JT; Bodaghi B; Couto C; Zierhut M; Acharya N; Pavesio C; Tay-Kearney ML; Neri P; Douglas K; Pathai S; Song AP; Kron M; Foster CS Semin Arthritis Rheum; 2019 Dec; 49(3):438-445. PubMed ID: 31301816 [TBL] [Abstract][Full Text] [Related]
8. Road to remission: a comprehensive review of therapy in uveitis. Siddique SS; Shah R; Suelves AM; Foster CS Expert Opin Investig Drugs; 2011 Nov; 20(11):1497-515. PubMed ID: 21936708 [TBL] [Abstract][Full Text] [Related]
9. Adalimumab in the treatment of non-infectious uveitis. Burek-Michalska A; Turno-Kręcicka A Adv Clin Exp Med; 2020 Oct; 29(10):1231-1236. PubMed ID: 33125196 [TBL] [Abstract][Full Text] [Related]
10. Miliary tuberculosis developing during adalimumab treatment for Behçet's disease with uveitis. Kim MJ; Jones N; Steeples LR BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567192 [TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the treatment of uveitis. Leung TG; Thorne JE Expert Opin Emerg Drugs; 2013 Dec; 18(4):513-21. PubMed ID: 24274613 [TBL] [Abstract][Full Text] [Related]
12. Systemic immunosuppressive therapies for uveitis in developing countries. Agrawal H; Doan H; Pham B; Khosla A; Babu M; McCluskey P; Nguyen QD; Sangwan V; Reddy S; Sawhney S; Tyagi M Indian J Ophthalmol; 2020 Sep; 68(9):1852-1862. PubMed ID: 32823402 [TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for the treatment of noninfectious uveitis. Pleyer U; Pohlmann D; Kardeş E; Poddubnyy D; Rademacher J Expert Opin Emerg Drugs; 2019 Sep; 24(3):173-190. PubMed ID: 31498689 [No Abstract] [Full Text] [Related]
14. Adalimumab in Patients with Active Noninfectious Uveitis. Jaffe GJ; Dick AD; Brézin AP; Nguyen QD; Thorne JE; Kestelyn P; Barisani-Asenbauer T; Franco P; Heiligenhaus A; Scales D; Chu DS; Camez A; Kwatra NV; Song AP; Kron M; Tari S; Suhler EB N Engl J Med; 2016 Sep; 375(10):932-43. PubMed ID: 27602665 [TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and current therapies for non-infectious uveitis. Wu X; Tao M; Zhu L; Zhang T; Zhang M Clin Exp Med; 2023 Aug; 23(4):1089-1106. PubMed ID: 36422739 [TBL] [Abstract][Full Text] [Related]
16. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Thomas AS Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945 [TBL] [Abstract][Full Text] [Related]
17. A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II. Lee K; Bajwa A; Freitas-Neto CA; Metzinger JL; Wentworth BA; Foster CS Expert Opin Biol Ther; 2014 Nov; 14(11):1651-66. PubMed ID: 25226284 [TBL] [Abstract][Full Text] [Related]
18. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302 [TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764 [TBL] [Abstract][Full Text] [Related]
20. Therapies in Development for Non-Infectious Uveitis. Sadiq MA; Agarwal A; Hassan M; Afridi R; Sarwar S; Soliman MK; Do DV; Nguyen QD Curr Mol Med; 2015; 15(6):565-77. PubMed ID: 26238367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]